Lee Wilson discovered she has a "100%" chance of developing ALS, after losing her father and grandmother to the disease ...

I pray that she carries the love that she felt tonight every day that she has," said friend Rita Monteiro, who organized the ...

The EMA recommended that NUZ-001, formerly monepantel, be granted orphan medicinal product designation to treat ALS in Europe ...

A Phase 2 trial testing oral ROCK inhibitor Bravyl in people with ALS is now fully enrolled at its highest dosing group.

Market 32/Price Chopper is presenting a check for nearly a quarter of a million dollars to St. Peter’s Health Partners on ...

Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug ...

ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord, ultimately leading to muscle weakness and paralysis. ALS is an orphan disease, but its ...

PLL Therapeutics focuses on restoring gut permeability. Its initial indication is Amyotrophic Lateral Sclerosis (ALS), a fatal motor neuron disease. The company’s therapy, PLL001, consists of several ...

Trace Neuroscience Launches with $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases, ...